Skip to content

IBD and Cannabinoid Medicine

IBD and Cannabinoid Medicine

With an estimated 3.1 million adults diagnosed with Irritable Bowel Disease (IBD) in the United States, it’s natural that many people are asking about the possible benefits of cannabis for the symptoms associated with IBD. In fact, the University of Michigan Health Department received so many questions regarding this issue, that they released a Q&A with one of their gastroenterologists on the subject. 

People suffering from IBD often have symptoms that can easily interfere with life’s daily activities.  Those symptoms include:

  • Abdominal cramps and pain
  • Diarrhea that may be bloody
  • Severe urgency to have a bowel movement
  • Fever
  • Weight loss
  • Loss of appetite
  • Iron deficiency anemia due to blood loss

With many states that allow medical marijuana including IBD in their ‘qualifying conditions’ list, patients have been able to use cannabinoid medicine in conjunction with their traditional treatment to find symptom relief.  Our data at Arfinn Med indicates that patients adding cannabinoid treatment to their regiment have seen an improvement in their symptoms, indicating a 3.9 out of 5.0 on our symptom relief scale.

A screenshot of a cell phone

Description automatically generated

If you are suffering from IBD and are interested in learning more about cannabinoid medicine, please reach out to your physician to discuss ways of incorporating it into your existing treatment. If your physician would like more information, please refer them to Arfinn Med and its EMR and data portal focusing on complimentary and alternative medicines (CAM).

Resources:

https://healthblog.uofmhealth.org/digestive-health/cannabis-for-treating-ibd-hope-or-hype

https://www.webmd.com/ibd-crohns-disease/inflammatory-bowel-syndrome#1

https://www.healthline.com/health/crohns-disease/facts-statistics-infographic#1

Stories you may be interested in

Assessing Health-Related Outcomes of Medical Cannabis Use among Older Persons: Findings from Colorado and Illinois

ABSTRACT Objectives To assess health-related outcomes associated with medical cannabis use among older patients in Colorado and Illinois enrolled in their home state’s medical cannabis program. Methods Cross-sectional data from anonymous surveys were collected from 139 persons over the age of 60 using medical cannabis in the past year. We used structural equation modeling (SEM)…
Read More

Data Migration During EMR Changes

One of the most challenging aspects when deciding to switch to a new EMR system is how to get existing data from the old system to the new system safely, securely and accurately.  Many times, the scope of this task is enough to force providers to remain with a subpar vendor even though there are…
Read More

Florida medical marijuana dispensary now sells the state’s first cannabis tablet

Even though Florida residents can finally smoke medical marijuana, one of the state’s largest cannabis companies is now offering it in tablet form. The company Curaleaf released the state’s first cannabis tablet on Sunday. The company’s two Orlando locations, at 775 N Semoran Blvd. and 12402 S Orange Blossom Trail, sell the mint-flavored tablets for $35 for a 30-quantity, child-resistant package. Read…
Read More

Substance in cannabis ‘could boost pancreatic cancer treatments’

A substance found in cannabis plants might boost treatments for patients with pancreatic cancer, research in mice has suggested. Cannabidiol, or CBD, is not psychoactive, meaning it does not produce feelings of being high in those who take it. It is extracted from hemp plants and is legal in the UK, although a CBD product…
Read More

CEO Spotlight: James West

As a former academic coordinator for the City University of New York Research Foundation and Medgar Evers College, CEO and co-founder of Arfinn Med, James West, has extensive experience in adult education and professional training programming. James put this extensive education to good use when he noticed that there was a direct need for a…
Read More

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More

Leave a Comment

You must be logged in to post a comment.